HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer

Molecular Endocrinology

Volumn 23, Issue 12, 2009, Pages 1963-1972

  Ai, Junkui ^a   Wang, Yujuan ^a   Dar, Javid A ^a   Liu, June ^a   Liu, Lingqi ^a   Nelson, Joel B ^a,b   Wang, Zhou ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE 6;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CASTRATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FIBROBLAST; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; RECEPTOR AFFINITY; RECEPTOR SENSITIVITY; TUMOR XENOGRAFT;

ACETYLATION; ANIMALS; BLOTTING, WESTERN; CASTRATION; CELL LINE, TUMOR; CELL PROLIFERATION; DIHYDROTESTOSTERONE; GENE EXPRESSION; HISTONE DEACETYLASES; HSP90 HEAT-SHOCK PROTEINS; HUMANS; HYDROXAMIC ACIDS; IMMUNOPRECIPITATION; MALE; MICE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 73249149751     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2009-0188     Document Type: Article

References (52)

1. Huggins C 1967 Endocrine-induced regression of cancers. Science 156:1050-1054
2. Grossmann ME, Huang H, Tindall DJ 2001 Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93:1687-1697
3. Culig Z, Hobisch A, Hittmair A, Peterziel H, Cato AC, Bartsch G, Klocker H 1998 Expression, structure, and function of androgen receptor in advanced prostatic carcinoma. Prostate 35:63-70
4. Chang C, Saltzman A, Yeh S, Young W, Keller E, Lee HJ, Wang C, Mizokami A 1995 Androgen receptor: an overview. Crit Rev Eukaryot Gene Expr 5:97-125
5. Huggins C, Hodges CV 1972 Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 22:232-240
6. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL 2004 Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33-39
7. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ 2002 Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 62:1008-1013
8. Shi XB, Ma AH, Tepper CG, Xia L, Gregg JP, Gandour-Edwards R, Mack PC, Kung HJ, deVere White RW 2004 Molecular alterations associated with LNCaP cell progression to androgen independence. Prostate 60:257-271
9. Scher HI, Sawyers CL 2005 Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgenreceptor signaling axis. J Clin Oncol 23:8253-8261
10. Debes JD, Tindall DJ 2004 Mechanisms of androgen-refractory prostate cancer. N Engl J Med 351:1488-1490
11. Taplin ME, Balk SP 2004 Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 91:483-490
12. Hara T, Nakamura K, Araki H, Kusaka M, Yamaoka M 2003 Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline. Cancer Res 63:5622-5628
13. Reddy GP, Barrack ER, Dou QP, Menon M, Pelley R, Sarkar FH, Sheng S 2006 Regulatory processes affecting androgen receptor expression, stability, and function: potential targets to treat hormone-refractory prostate cancer. J Cell Biochem 98:1408-1423
14. Huang ZQ, Li J, Wong J 2002 AR possesses an intrinsic hormoneindependent transcriptional activity. Mol Endocrinol 16:924-937
15. Gregory CW, Johnson Jr RT, Moehler JL, French FS, Wilson EM 2001 Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 61: 2892-2898
16. Veldscholte J, Berrevoets CA, Brinkmann AO, Grootegoed JA, Mulder E 1992 Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry 31: 2393-2399
17. Picard D, Yamamoto KR 1987 Two signals mediate hormone-dependent nuclear localization of the glucocorticoid receptor. EMBO J 6:3333-3340
18. Yeh S, Chang HC, Miyamoto H, Takatera H, Rahman M, Kang HY, Thin TH, Lin HK, Chang C 1999 Differential induction of the androgen receptor transcriptional activity by selective androgen receptor coactivators. Keio J Med 48:87-92
19. Pratt WB, Galigniana MD, Morishima Y, Murphy PJ 2004 Role of molecular chaperones in steroid receptor action. Essays Biochem 40:41-58
20. Gronemeyer H, Gustafsson JA, Laudet V 2004 Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 3:950-964
21. Georget V, Lobaccaro JM, Terouanne B, Mangeat P, Nicolas JC, Sultan C 1997 Trafficking of the androgen receptor in living cells with fused green fluorescent protein-androgen receptor. Mol Cell Endocrinol 129:17-26
22. Tyagi RK, Lavrovsky Y, Ahn SC, Song CS, Chatterjee B, Roy AK 2000 Dynamics of intracellular movement and nucleocytoplasmic recycling of the ligand-activated androgen receptor in living cells. Mol Endocrinol 14:1162-1174
23. Kovacs JJ, Cohen TJ, Yao TP 2005 Chaperoning steroid hormone signaling via reversible acetylation. Nucl Recept Signal 3:e004
24. Pratt WB, Toft DO 1997 Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev 18: 306-360
25. DeFranco DB, Ramakrishnan C, Tang Y 1998 Molecular chaperones and subcellular trafficking of steroid receptors. J Steroid Biochem Mol Biol 65:51-58
26. Neckers L 2002 Heat shock protein 90 inhibition by 17-allylamino-17-demethoxygeldanamycin: a novel therapeutic approach for treating hormone-refractory prostate cancer. Clin Cancer Res 8:962-966
27. Georget V, Térouanne B, Nicolas JC, Sultan C 2002 Mechanism of antiandrogen action: key role of hsp90 in conformational change and transcriptional activity of the androgen receptor. Biochemistry 41:11824-11831
28. Saporita AJ, Ai J, Wang Z 2007 The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells. Prostate 67:509-520
29. Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, Yoshida M, Toft DO, Pratt WB, Yao TP 2005 HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 18:601-607
30. Murphy PJ, Morishima Y, Kovacs JJ, Yao TP, Pratt WB 2005 Regulation of the dynamics of hsp90 action on the glucocorticoid receptor by acetylation/deacetylation of the chaperone. J Biol Chem 280:33792-33799
31. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P, Seto E, Bhalla K 2005 Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 280: 26729-26734
32. Aoyagi S, Archer TK 2005 Modulating molecular chaperone Hsp90 functions through reversible acetylation. Trends Cell Biol 15:565-567
33. Kekatpure VD, Dannenberg AJ, Subbaramaiah K 2009 HDAC6 modulates HSP90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling. J Biol Chem 284:7436-7445
34. Fang Y, Fliss AE, Robins DM, Caplan AJ 1996 Hsp90 regulates androgen receptor hormone binding affinity in vivo. J Biol Chem 271:28697-28702
35. Basak S, Pookot D, Noonan EJ, Dahiya R 2008 Genistein downregulates androgen receptor by modulating HDAC6-Hsp90 chaperone function. Mol Cancer Ther 7:3195-3202
36. Guardiola AR, Yao TP 2002 Molecular cloning and characterization of a novel histone deacetylase HDAC10. J Biol Chem 277: 3350-3356
37. Hager GL, Lim CS, Elbi C, Baumann CT 2000 Trafficking of nuclear receptors in living cells. J Steroid Biochem Mol Biol 74:249-254
38. Nakauchi H, Matsuda K, Ochiai I, Kawauchi A, Mizutani Y, Miki T, Kawata M 2007 A differential ligand-mediated response of green fluorescent protein-tagged androgen receptor in living prostate cancer and non-prostate cancer cell lines. J Histochem Cytochem 55: 535-544
39. Zhang Y, Kwon S, Yamaguchi T, Cubizolles F, Rousseaux S, Kneissel M, Cao C, Li N, Cheng HL, Chua K, Lombard D, Mizeracki A, Matthias G, Alt FW, Khochbin S, Matthias P 2008 Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol 28:1688-1701
40. Scroggins BT, Robzyk K, Wang D, Marcu MG, Tsutsumi S, Beebe K, Cotter RJ, Felts S, Toft D, Karnitz L, Rosen N, Neckers L 2007 An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol Cell 25:151-159
41. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP 1983 LNCaP model of human prostatic carcinoma. Cancer Res 43:1809-1818
42. Lee C, Sutkowski DM, Sensibar JA, Zelner D, Kim I, Amsel I, Shaw N, Prins GS, Kozlowski JM 1995 Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 136:796-803
43. Welsbie DS, Xu J, Chen Y, Borsu L, Scher HI, Rosen N, Sawyers CL 2009 Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res 69:958-966
44. Walton TJ, Li G, Seth R, McArdle SE, Bishop MC, Rees RC 2008 DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor β and induce apoptosis in prostate cancer cell-lines. Prostate 68:210-222
45. Wang LG, Ossowski L, Ferrari AC 2004 Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line. Oncogene 23:5175-5184
46. Korkmaz CG, Frønsdal K, Zhang Y, Lorenzo PI, Saatcioglu F 2004 Potentiation of androgen receptor transcriptional activity by inhibition of histone deacetylation-rescue of transcriptionally compromised mutants. J Endocrinol 182:377-389
47. Shang Y, Myers M, Brown M 2002 Formation of the androgen receptor transcription complex. Mol Cell 9:601-610
48. Solit DB, Zheng FF, Drobnjak M, Munster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI, Rosen N 2002 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 8:986-993
49. Heath EI, Hillman DW, Vaishampayan U, Sheng S, Sarkar F, Harper F, Gaskins M, Pitot HC, Tan W, Ivy SP, Pili R, Carducci MA, Erlichman C, Liu G 2008 A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res 14:7940-7946
50. Saporita AJ, Zhang Q, Navai N, Dincer Z, Hahn J, Cai X, Wang Z 2003 Identification and characterization of a ligand-regulated nuclear export signal in androgen receptor. J Biol Chem 278:41998-42005
51. Fischle W, Dequiedt F, Fillion M, Hendzel MJ, Voelter W, Verdin E 2001 Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo. J Biol Chem 276:35826-35835
52. Gao YS, Hubbert CC, Lu J, Lee YS, Lee JY, Yao TP 2007 Histone deacetylase 6 regulates growth factor-induced actin remodeling and endocytosis. Mol Cell Biol 27:8637-8647